Efficacy/Safety of Ecraprost in Lipid Emulsion for Treatment of Critical Leg Ischemia Due to Peripheral Arterial Disease
Status:
Completed
Trial end date:
2005-11-01
Target enrollment:
Participant gender:
Summary
Ecraprost in lipid emulsion is being developed for the treatment of Critical leg ischemia
(CLI), which is the most severe form of peripheral arterial disease (PAD); This trial is
designed to assess the efficacy and safety of the drug in the treatment of CLI.